LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) and Dey, L.P. (DEY), today began the nationwide launch of ZYFLO CR™ (zileuton) extended-release tablets, a twice-daily medication for the prevention and chronic treatment of asthma in patients 12 years of age and older. With a combined 240-person U.S. sales force, Critical Therapeutics and DEY have begun promoting ZYFLO CR to a targeted group of approximately 18,000 allergists, pulmonologists and primary care physicians throughout the United States.
